setidegrasib
Phase 3An investigational KRAS G12D protein degrader in a phase 3 comparison with docetaxel for previously treated, progressing KRAS G12D-mutated advanced NSCLC.
FROM PUBLIC EVENTS · 2026-11-18
Late clinical · capacity Advancing late-stage development with first-patient dosing announced in a Phase 3 trial of setidegrasib for KRAS G12D-mutated lung cancer
Roles often seen at this stageClinical & PV · Regulatory affairs · Research & development
アステラス製薬
Official name · アステラス製薬
Conducts pharmaceutical R&D, including targeted protein degradation candidates in oncology.
An investigational KRAS G12D protein degrader in a phase 3 comparison with docetaxel for previously treated, progressing KRAS G12D-mutated advanced NSCLC.
The September 24 release announced the first patient dosed in that phase 3 study; it did not separately specify the dosing date.
Official role guide
Observed 2026-10-04
Information from a role guide does not establish a current vacancy.
Recruitment program
Observed 2026-10-04
A brief based on selected official material, not an exhaustive product or vacancy list.